Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia.
Mast cell tumours (MCTs) are relatively common tumours of cats, and are the second most common cutaneous tumours in cats in the USA. While the primary splenic form of the disease is far less common, it is usually associated with more severe clinical signs. Signalment, clinical and survival characteristics of mast cell neoplasia were characterised in 41 cats. The most common tumour location was cutaneous/subcutaneous head and trunk. Stage 1a was the most common tumour stage at first diagnosis (n=20), followed by stage 4 (both stage 4a and stage 4b; n=10). Of 22 cats that underwent excisional biopsy, mast cell neoplasia recurred in four cats during the study period. Three of the 41 cats presented with simultaneous cutaneous and either splenic or lymph node tumours. A comparison between cats with only cutaneous tumours (n=30) and those with tumours involving the spleen or lymph nodes (n=11) showed longer survival times for the cutaneous-only group (P=0.031). Twelve of the 41 cats died of mast cell neoplasia during the study period. When a subgroup of cats with only cutaneous tumours (no lymph node or visceral involvement) were divided according to whether there were multiple (five or more) tumours (n=6) or a single tumour (n=19), cats with single tumours survived longer than those with multiple tumours (P=0.001). Solitary cutaneous feline MCTs without spread to the lymph nodes usually manifest as benign disease with a relatively protracted course. However, multiple cutaneous tumours, recurrent tumours and primary splenic disease should receive a guarded prognosis due to the relatively short median survival times associated with these forms of the disease.
Litster
Annette L
AL
School of Veterinary Science, University of Queensland, St. Lucia, Qld 4072, Australia. catvet@uq.edu.au
Sorenmo
Karin U
KU
D000818:Animals; D002371:Cat Diseases / Q000473:pathology*; D002415:Cats; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D012515:Mast-Cell Sarcoma / Q000473:pathology / Q000662:veterinary*; D009367:Neoplasm Staging; D011379:Prognosis; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000473:pathology / Q000662:veterinary*; D016019:Survival Analysis